Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moleculin Biotech ( (MBRX) ) just unveiled an update.
On March 19, 2026, Moleculin Biotech, Inc. reported that it is using a new corporate presentation, which has been posted on its website for stakeholders. The materials were furnished in connection with a Current Report on Form 8-K, underscoring an effort to update investors and the market on the company’s status without incorporating the presentation into its formal securities filings.
The most recent analyst rating on (MBRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting these somewhat are positive corporate developments (clinical progress, IP, and regained Nasdaq compliance), while valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. operates in the biopharmaceutical industry, focusing on the development of oncology drug candidates and related therapeutics. The company targets serious diseases, including various forms of cancer, positioning its pipeline for investors and partners interested in high-risk, high-reward clinical-stage assets.
Average Trading Volume: 182,409
Technical Sentiment Signal: Sell
Current Market Cap: $10.26M
For an in-depth examination of MBRX stock, go to TipRanks’ Overview page.